Targeting human Mas-related G protein-coupled receptor X1 to inhibit persistent pain

Zhe Li, Pang Yen Tseng, Vinod Tiwari, Qian Xu, Shao Qiu He, Yan Wang, Qin Zheng, Liang Han, Zhiping Wu, Anna L. Blobaum, Yiyuan Cui, Vineeta Tiwari, Shuohao Sun, Yingying Cheng, Julie H Y Huang-Lionnet, Yixun Geng, Bo Xiao, Junmin Peng, Corey R Hopkins, Srinivasa N. Raja & 2 others Yun Guan, Xinzhong Dong

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Human Mas-related G protein-coupled receptor X1 (MRGPRX1) is a promising target for pain inhibition, mainly because of its restricted expression in nociceptors within the peripheral nervous system. However, constrained by species differences across Mrgprs, drug candidates that activate MRGPRX1 do not activate rodent receptors, leaving no responsive animal model to test the effect on pain in vivo. Here, we generated a transgenic mouse line in which we replaced mouse Mrgprs with human MrgprX1. This humanized mouse allowed us to characterize an agonist [bovine adrenal medulla 8-22 (BAM8-22)] and a positive allosteric modulator (PAM), ML382, of MRGPRX1. Cellular studies suggested that ML382 enhances the ability of BAM8-22 to inhibit high-voltage-activated Ca2+ channels and attenuate spinal nociceptive transmission. Importantly, both BAM8-22 and ML382 effectively attenuated evoked, persistent, and spontaneous pain without causing obvious side effects. Notably, ML382 by itself attenuated both evoked pain hypersensitivity and spontaneous pain in MrgprX1 mice after nerve injury without acquiring coadministration of an exogenous agonist. Our findings suggest that humanized MrgprX1 mice provide a promising preclinical model and that activating MRGPRX1 is an effective way to treat persistent pain.

Original languageEnglish (US)
Pages (from-to)E1996-E2005
JournalProceedings of the National Academy of Sciences of the United States of America
Volume114
Issue number10
DOIs
StatePublished - Mar 7 2017
Externally publishedYes

Fingerprint

G-Protein-Coupled Receptors
Pain
Nociceptors
Aptitude
Peripheral Nervous System
Transgenic Mice
Rodentia
Hypersensitivity
Animal Models
Wounds and Injuries
Pharmaceutical Preparations
bovine adrenal medulla 8-22

Keywords

  • DRG neurons
  • GPCR
  • MrgprX1
  • Pain
  • Positive allosteric modulator

ASJC Scopus subject areas

  • General

Cite this

Targeting human Mas-related G protein-coupled receptor X1 to inhibit persistent pain. / Li, Zhe; Tseng, Pang Yen; Tiwari, Vinod; Xu, Qian; He, Shao Qiu; Wang, Yan; Zheng, Qin; Han, Liang; Wu, Zhiping; Blobaum, Anna L.; Cui, Yiyuan; Tiwari, Vineeta; Sun, Shuohao; Cheng, Yingying; Huang-Lionnet, Julie H Y; Geng, Yixun; Xiao, Bo; Peng, Junmin; Hopkins, Corey R; Raja, Srinivasa N.; Guan, Yun; Dong, Xinzhong.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, No. 10, 07.03.2017, p. E1996-E2005.

Research output: Contribution to journalArticle

Li, Z, Tseng, PY, Tiwari, V, Xu, Q, He, SQ, Wang, Y, Zheng, Q, Han, L, Wu, Z, Blobaum, AL, Cui, Y, Tiwari, V, Sun, S, Cheng, Y, Huang-Lionnet, JHY, Geng, Y, Xiao, B, Peng, J, Hopkins, CR, Raja, SN, Guan, Y & Dong, X 2017, 'Targeting human Mas-related G protein-coupled receptor X1 to inhibit persistent pain', Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 10, pp. E1996-E2005. https://doi.org/10.1073/pnas.1615255114
Li, Zhe ; Tseng, Pang Yen ; Tiwari, Vinod ; Xu, Qian ; He, Shao Qiu ; Wang, Yan ; Zheng, Qin ; Han, Liang ; Wu, Zhiping ; Blobaum, Anna L. ; Cui, Yiyuan ; Tiwari, Vineeta ; Sun, Shuohao ; Cheng, Yingying ; Huang-Lionnet, Julie H Y ; Geng, Yixun ; Xiao, Bo ; Peng, Junmin ; Hopkins, Corey R ; Raja, Srinivasa N. ; Guan, Yun ; Dong, Xinzhong. / Targeting human Mas-related G protein-coupled receptor X1 to inhibit persistent pain. In: Proceedings of the National Academy of Sciences of the United States of America. 2017 ; Vol. 114, No. 10. pp. E1996-E2005.
@article{848fd3032496497d9555e6b8fa15799b,
title = "Targeting human Mas-related G protein-coupled receptor X1 to inhibit persistent pain",
abstract = "Human Mas-related G protein-coupled receptor X1 (MRGPRX1) is a promising target for pain inhibition, mainly because of its restricted expression in nociceptors within the peripheral nervous system. However, constrained by species differences across Mrgprs, drug candidates that activate MRGPRX1 do not activate rodent receptors, leaving no responsive animal model to test the effect on pain in vivo. Here, we generated a transgenic mouse line in which we replaced mouse Mrgprs with human MrgprX1. This humanized mouse allowed us to characterize an agonist [bovine adrenal medulla 8-22 (BAM8-22)] and a positive allosteric modulator (PAM), ML382, of MRGPRX1. Cellular studies suggested that ML382 enhances the ability of BAM8-22 to inhibit high-voltage-activated Ca2+ channels and attenuate spinal nociceptive transmission. Importantly, both BAM8-22 and ML382 effectively attenuated evoked, persistent, and spontaneous pain without causing obvious side effects. Notably, ML382 by itself attenuated both evoked pain hypersensitivity and spontaneous pain in MrgprX1 mice after nerve injury without acquiring coadministration of an exogenous agonist. Our findings suggest that humanized MrgprX1 mice provide a promising preclinical model and that activating MRGPRX1 is an effective way to treat persistent pain.",
keywords = "DRG neurons, GPCR, MrgprX1, Pain, Positive allosteric modulator",
author = "Zhe Li and Tseng, {Pang Yen} and Vinod Tiwari and Qian Xu and He, {Shao Qiu} and Yan Wang and Qin Zheng and Liang Han and Zhiping Wu and Blobaum, {Anna L.} and Yiyuan Cui and Vineeta Tiwari and Shuohao Sun and Yingying Cheng and Huang-Lionnet, {Julie H Y} and Yixun Geng and Bo Xiao and Junmin Peng and Hopkins, {Corey R} and Raja, {Srinivasa N.} and Yun Guan and Xinzhong Dong",
year = "2017",
month = "3",
day = "7",
doi = "10.1073/pnas.1615255114",
language = "English (US)",
volume = "114",
pages = "E1996--E2005",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "10",

}

TY - JOUR

T1 - Targeting human Mas-related G protein-coupled receptor X1 to inhibit persistent pain

AU - Li, Zhe

AU - Tseng, Pang Yen

AU - Tiwari, Vinod

AU - Xu, Qian

AU - He, Shao Qiu

AU - Wang, Yan

AU - Zheng, Qin

AU - Han, Liang

AU - Wu, Zhiping

AU - Blobaum, Anna L.

AU - Cui, Yiyuan

AU - Tiwari, Vineeta

AU - Sun, Shuohao

AU - Cheng, Yingying

AU - Huang-Lionnet, Julie H Y

AU - Geng, Yixun

AU - Xiao, Bo

AU - Peng, Junmin

AU - Hopkins, Corey R

AU - Raja, Srinivasa N.

AU - Guan, Yun

AU - Dong, Xinzhong

PY - 2017/3/7

Y1 - 2017/3/7

N2 - Human Mas-related G protein-coupled receptor X1 (MRGPRX1) is a promising target for pain inhibition, mainly because of its restricted expression in nociceptors within the peripheral nervous system. However, constrained by species differences across Mrgprs, drug candidates that activate MRGPRX1 do not activate rodent receptors, leaving no responsive animal model to test the effect on pain in vivo. Here, we generated a transgenic mouse line in which we replaced mouse Mrgprs with human MrgprX1. This humanized mouse allowed us to characterize an agonist [bovine adrenal medulla 8-22 (BAM8-22)] and a positive allosteric modulator (PAM), ML382, of MRGPRX1. Cellular studies suggested that ML382 enhances the ability of BAM8-22 to inhibit high-voltage-activated Ca2+ channels and attenuate spinal nociceptive transmission. Importantly, both BAM8-22 and ML382 effectively attenuated evoked, persistent, and spontaneous pain without causing obvious side effects. Notably, ML382 by itself attenuated both evoked pain hypersensitivity and spontaneous pain in MrgprX1 mice after nerve injury without acquiring coadministration of an exogenous agonist. Our findings suggest that humanized MrgprX1 mice provide a promising preclinical model and that activating MRGPRX1 is an effective way to treat persistent pain.

AB - Human Mas-related G protein-coupled receptor X1 (MRGPRX1) is a promising target for pain inhibition, mainly because of its restricted expression in nociceptors within the peripheral nervous system. However, constrained by species differences across Mrgprs, drug candidates that activate MRGPRX1 do not activate rodent receptors, leaving no responsive animal model to test the effect on pain in vivo. Here, we generated a transgenic mouse line in which we replaced mouse Mrgprs with human MrgprX1. This humanized mouse allowed us to characterize an agonist [bovine adrenal medulla 8-22 (BAM8-22)] and a positive allosteric modulator (PAM), ML382, of MRGPRX1. Cellular studies suggested that ML382 enhances the ability of BAM8-22 to inhibit high-voltage-activated Ca2+ channels and attenuate spinal nociceptive transmission. Importantly, both BAM8-22 and ML382 effectively attenuated evoked, persistent, and spontaneous pain without causing obvious side effects. Notably, ML382 by itself attenuated both evoked pain hypersensitivity and spontaneous pain in MrgprX1 mice after nerve injury without acquiring coadministration of an exogenous agonist. Our findings suggest that humanized MrgprX1 mice provide a promising preclinical model and that activating MRGPRX1 is an effective way to treat persistent pain.

KW - DRG neurons

KW - GPCR

KW - MrgprX1

KW - Pain

KW - Positive allosteric modulator

UR - http://www.scopus.com/inward/record.url?scp=85014605946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014605946&partnerID=8YFLogxK

U2 - 10.1073/pnas.1615255114

DO - 10.1073/pnas.1615255114

M3 - Article

VL - 114

SP - E1996-E2005

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 10

ER -